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Reproductive problems encompass a multiplicity of diseases 
including sterility, infertility, abortion (miscarriage), stillbirth, 
congenital malformations (resulting from environmental or 
hereditary etiologies), fetal growth retardation, and prematu- 
rity. These clinical problems occur commonly in the general 
population and, therefore, environmental causes are not 
always easy to corroborate (Table 15.1). Severe congenital 
malformations occur in 3% of births; according to the Center 
for Disease Control, they include those birth defects that cause 
death, hospitalization, and mental retardation, and those that 
necessitate significant or repeated surgical procedures, are dis- 
figuring, or interfere with physical performance. This means 
that each year in the USA, 120000 babies are born with severe 
birth defects. Genetic disease occurs in approximately 11 % of 
births, and spontaneous mutations account for approximately 
2-3% of genetic disease. This spontaneous mutation rate pres- 
ents difficulties when determining the proportion of mutations 
that are induced from preconception exposure to environ- 
mental mutagens. 
There have been dramatic advances in our-understanding of 
the causes of human birth defects. In earlier times, supersti- 
tion, ignorance, and prejudice played a major role in explain- 
.ing why birth defects occurred. Reproductive problems have 
been viewed throughout history as diseases of affliction, along 
with cancer, psychiatric illness, and hereditary diseases. The 
stigma associated with birth defects has primitive beginnings 
and persists today; in the minds of many, even the most sophis- 
ticated, a birth defect is felt to be some form of punishment 
for previous misdeeds.14 Ancient Babylonian writings recount 
tales of mothers being put to death because they delivered 
malformed infants. In the seventeenth century, one George 
Spencer was slain by the Puritans in New Haven having been 
convicted of fathering a cyclopean pig; the Puritans were 
unable to differentiate between George Spencer's cataract and 
the malformed pig's cloudy cornea.' More recently, the situa- 
tion has been reversed and the responsibility for reproductive 
problems such as congenital malformations, infertility, abor- 
tions, and hereditary diseases is often blamed on others, for 
example, environmental agents dispensed by healthcare 
providers or utilized by emp10yers.l.~ 
Reproductive problems alarm the public, the press, and sci- 
entists to a greater degree than many other diseases. Severely 
malformed children are disquieting to healthcare providers, 
especially if they are not experienced in dealing with such 
problems; no physician will be comfortable informing a family 
that their child was born without arms and legs. The objec- 
tive evaluation of the environmental causes of reproductive 
diseases is clouded by the emotional climate that surrounds 
these diseases, resulting in the expression of partisan positions 
that either diminish or magnify the environmental risks. These 
nonobjective opinions can be expressed by scientists, the laity, 
or the It is the responsibility of every physician to be 
aware of the emotionally charged situation when a family has 
a child with a birth defect; an inadvertent comment from 
medical staff attending delivery can have grave consequences 
for the physician and the family. Comments such as, "Oh, you 
had a radiograph during your pregnancy," or "You did not 
tell me that you were prescribed tetracycline while you were 
pregnant," can direct the patient's family to an attorney rather 
than to a teratology or genetic counselor. . 
At present, the etiology of congenital malformations can be 
divided into three categories: unknown, genetic, and environ- 
mental. Unfortunately, the largest group (65-7546) has an 
unknown etiology, whereas the most common known cause is 
genetic (15-25%).7-9 Environmental factors account for 10% 
of congenital malformations. Over 50 teratogenic environ- 
mental drugs, chemicals, and physical agents have been 
described9-l2 by clinical dysmorphologists using modern 
epidemiological  tool^.'^-'^ The basic science and clinical rules 
for evaluating teratogenic risks have been e~tablished.~' The 
purpose of this chapter is to inform clinicians about envi- 
ronmental drugs, chemicals, and physical agents that have 
been documented to produce congenital malformations and 
reproductive effects, and to indicate that the multdude of 
teratogenic agents accounts for only a small proportion %f 
malformations. 
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Table 15.1 Background reproductive risks in pregnancy. 
*. 
Reproductive risk , Frequency 
Immunologically and clinically diagnosed spontaneous abortions per million conceptions 350 000 
Clinically recognized spontaneous abortions per million clinically recognized pregnancies 150000 
Genetic diseases per million births: 110000 
Multifactorial or polygenic genetic environmental interactions (i.e., neural tube defects, cleft lip, hypospadias, 90 000 
hyperlipidemia, diabetes) 
Dominantly inherited disease (i.e., achondroplasia, Huntington's chorea, neurofibromatosis) 10000 
Autosomal and sex-linked genetic disease (i.e., cystic fibrosis, hemophilia, sickle-cell disease, thalassemia) 1200 
'Cytogenetic (chromosomal abnormalities) (i.e., Down syndrome (trisomy 21), trisomies 13 and 18, Turner syndrome, 5 000 
22q deletion, etc.) 
New mutations* 3 000 
Severe congenital malformationst per million births (resulting from all causes of birth defects: genetic, unknown, 30 000 
environmental) 
Prematurity per million births 40 000 
Fetal growth retardation per million births 30 000 
Stillbirths (> 20 weeks) per million births 2000-20900 
Infertility 7% of couples 
Modified from ref. 11. 
'The mutation rate for many genetic diseases can be calculated; this can be readily performed with dominantly inherited diseases when 
offspring are born with a dominant genetic disease and neither parent has the disease. 
tcongenital malformations have multiple etiologies including a significant proportion that are genetic. 
Basic principles of teratology 
To label a n  environmental agent as teratogenic it is necessary 
to  characterize the dose, route of exposure, and stage of preg- 
nancy when the exposure occurred. A SO-mg dose of thalido- 
mide administered on the 26th day post conception has a 
significant risk of maiforming the embryo. The same dose 
taken during the 10th week of gestation will not result in con- 
genital malformations, and I mg of thalidomide taken a t  any 
time during pregnancy will have no effect o n  the developing 
embryo. X-ray irradiation can be t e r a t o g e n i ~ ; ~ ' - ~ ~  however, if 
the dose is too low or the X-ray does not directly expose the 
embryo, there is no increased risk of congenital malforma- 
t i o n ~ . ~  Therefore a list of teratogens indicates only teratogenic 
potential; evaluation of the dose and time of exposure may 
indicate that there is no teratogenic risk or  that the risk is 
significant. 
Physicians must be careful to  carry out a thorough evalua- 
tion of the risks faced by a woman exposed to drugs and chem- 
icals during pregnancy, and before alleging that a child's 
malformations result from exposure to  a n  environmental 
agent. Clinical teratology and genetics is not emphasized in 
medical schools and residency education programs. However, 
clinicians have a multitude of educational aids to  assist them 
in their evaluations; these include consultations with clinical 
teratologists and geneticists, the medical literature, and the 
Online Mendelian Inheritance of Man (OMIM) ~ e b s i t e . ' ~  
The analysis of human and animal studies on the repro- 
ductive effects of environmental agents should be guided by 
the basic principles of teratology and developmental b i ~ l o g y ; ~  
these principles are outlined in Table 15.2.2s"2 
The etiology of 
congenital malformations 
As mentioned earlier, the etiology of congenital malformations 
can be divided into three categories: unknown, genetic, and 
environmental (Table 15.3). A significant proportion of con- 
genital malformations of unknown etiology are likely to  have 
an important genetic component. Mhlformations with an 
increased recurrent risk such as cleft lip and palate, anen- 
cephaly, spina bifida, certain congenital heart diseases, pyloric 
stenosis, hypospadias, inguinal hernia, talipes equinovarus, 
and congenital dislocation of the hip fit into the category of 
multifactorial disease as well as that of polygenic inherited 
d i ~ e a s e . ~ ~ , ~ ~  The multifactoriaVthreshold hypothesis postulates 
the modulation of a continuum of genetic characteristics by 
intrinsic and extrinsic (environmental) factors. 
A significant percentage of spontaneous errors of develop- 
ment can occur without apparent abnormalities of the genome 
or  environmental influences; these are due to the statistical 
probability of errors in the developmental process, similar to  
the concept of spontaneous mutation, and mean that we may 
never achieve our goal of eliminating birth defects. It is esti- , 
mated that the majority of all miscarriages occur early in preg- 
nancy, many within the first 3 weeks of deve!opment. The 
World Health Organization estimated that 1 5 %  of all clini- 
cally recognizable pregnancies end in spontaneous abortion, 
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Table 15.2 Basic scientific principles of teratology. 
Principle Description 
- - -- - - 
C 
Exposure to teratogens follows a toxicological There is a threshold below which no teratogenic effect will be observed. As the 
dose-response curve dose of the teratogen is increased, both the severity and frequency of 
reproductive effects will increase (Fig. 15.1) 
The embryonic stage at which exposure occurs will Some teratogens have a broad period of embryonic sensitivity while others have 
determine what effects, if any, a teratogen will have a very narrow period of sensitivity 
Most teratogens have a confined group of congenital Known teratogens may be presumptively implicated by the spectrum of 
malformations referred to as the syndrome of the malformations they produce. It is easier to exclude an agent as a cause of a 
agent's effects birth defect than to definitively prove it was responsible because of the 
existence of genocopies of some teratogenic syndromes 
No teratogen can produce every type of malformation The presence of certain malformations can eliminate the possibility that a 
particular teratogenic agent was responsible because those malformations have 
not been demonstrated to be part of the syndrome caused by the teratogen, 
or because production of the malformation is not biologically plausible for 
that particular alleged teratogen 
Based on concepts from ref. 20. 
Table 15.3 Etiology of human congenital malformations observed during the first year of life. 
Suspected cause Percent of total 
Unknown 65-75 
Polygenic 
Multifactorial (gene-environment interactions) 
Spontaneous errors of development 
Synergistic interactions of teratogens 
Genetic 
Autosomal and sex-linked inherited genetic disease 
Cytogenetic (chromosomal abnormalities) 
New mutations 
Environmental 10 
Maternal conditions: alcoholism, diabetes, endocrinopathies, phenylketonuria, smoking and nicotine, starvation, 4 
nutritional deficits 
Infectious agents: rubella, toxoplasmosis, syphilis, herpes simplex, cytomegalovirus, varicella zoster, Venezuelan 3 
equine encephalitis, parvovirus B19 
Mechanical problems (deformations): amniotic band constrictions, umbilical cord constraint, disparity in uterine 1-2 
size and uterine contents 
Chemicals, prescription drugs, high-dose ionizing radiation, hyperthermia < 1 
Modified from ref. 8. 
many (50-60%) resulting from chromosomal abnormali- 
Finally, 3-6% of offspring are  malformed, which rep- 
resents the background risk for abnormal human development 
(Table 15.1). 
Factors that affect susceptibility to 
developmental toxicants 
A basic tenet 'of environmentally produced malformations is 
that teratogens o r  a teratogenic milieu have certain character- 
istics in common a n d  follow certain basic principles. These 
principles determine the  quantitative and qualitative aspects 
of environmentally produced malformations. 
Embryonic stage 
T h e  risk of a n  exposure to a developmental toxicant resulting 
in morphological anomalies o r  intrauterine death depends o n  
the dose a n d  the embryonic o r  fetal stage a t  which exposure 
occurs. T h e  period when a n  exposure occurs will determine 
which structures are  most  susceptible t o  the deleterious effects 
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Table 15.4 Developmental stage sensitivity to thalidomide-induced 
limb reduction defects in the human. 
Days from conception Limb reduction defects 
' for induction of defects 
21-26 Thumb aplasia 
22-23 Microtia, deafness 
23-34 Hip dislocation 
2 4 2 9  Amelia, upper limbs 
24-33 Phocomelia, upper limbs 
25-31 - Preaxial aplasia, upper limbs 
27-31 Amelia, lower limbs 
28-33 Preaxial aplasia, lower limbs; 
phocomelia, lower limbs; femoral 
hypoplasia; girdle hypoplasia 
' 33-36 Triphalangeal thumb 
Modified from ref. 4. 
of the drug or chemical and to  what extent the embryo can 
repair the damage. The period of sensitivity may be narrow 
or broad, depending on the environmental agent and the 
malformation in question. Limb defects produced by thali- 
domide have a very short period of susceptibility4 (2 weeks; 
Table 15.4), whereas microcephaly, produced by radia- 
tion, has a long period of susceptibility (weeks 8-15 of 
pregnan~y) .~  
The embryo is most sensitive t o  the lethal effects of drugs 
and chemicals during the period of embryonic development, 
from fertilization through the early postimplantation stage. 
Surviving embryos have malformation rates that are similar to 
those of control subjects because significant cell loss or  chro- 
mosome abnormalities at  these stages has a high likelihood of 
resulting in embryonic death, not because malformations 
cannot be produced a t  this stage. Because of the omnipoten- 
tiality of early embryonic cells, surviving embryos have a high 
probability of having malformation rates that are similar to 
embryos that have not been exposed. 
The period of organogenesis (from day 1 8  through about 
day 40 post conception in the human) is the period of great- 
est sensitivity to teratogenic insults and when most gross 
anatomic malformations can be induced. Most environmen- 
tally produced major malformations occur before the 36th day 
post conception in the human. The exceptions are malforma- 
tions of the genito-urinary system, the palate, and the brain, 
o r  deformations due to  problems of constraint, disruption or  
destruction. 
The fetal period is characterized by histogenesis involving 
cell growth, differentiation, and migration. Agents that result 
in cell depletion, vascular disruption, necrosis, specific tissue 
or organ pathology, physiological decompensation, o r  severe 
growth retardation have the potential to  cause deleterious 
effects throughout gestation. The fetus is most sensitive to  the 
induction of mental retardation and microcephaly at  the end 
of the first and the beginning of the second trimester. Other 
permanent neurological effects can be induced in the second 
and third trimesters. Effects such as cell depletion or  func- 
tional abnormalities, not readily apparent at  birth, may give 
rise to  changes in behavior or fertility which are only appar- 
ent later in life. The last gestational day on which certain 
malformations may be induced in the human is presented in 
Table 15.5. 
Dose or magnitude of the exposure 
The quantitative correlation between the magnitude of the 
embryopathic effects and the dose of a drug, chemical, o r  
other agent is referred to  as the dose-response relationship. 
This is extremely important when comparing effects among 
different species because the use of mgtkg doses are, a t  best, 
rough approximations. Dose equivalence for drugs and chem- 
icals between humans and other species can be accomplished 
only by performing pharmacokinetic studies, metabolic 
studies, and dose-response investigations, whereas'ionizing 
radiation exposures in rads or sieverts (Sv) are similar in most 
mammalian species.' The response should be interpreted care- 
fully. For example, a substance given in large enough amounts 
to cause maternal toxicity is also likely to  have deleterious 
effects on the embryo such as death, growth retardation, o r  
retarded development. Also, it is unlikely that progesterone o r  
its synthetic analogues are involved in congenital teratogene- 
sis because the steroid receptors that are necessary for natu- 
rally occurring and synthetic progestin action are absent from 
nonreproductive tissues early in d e ~ e l o p m e n t . ' ~ ~ '  Several 
considerations affect the interpretation of dose-response rela- 
tionships and these are outlined in Table 15.6. 
Threshold dose 
The threshold dose is the dose b l o w  which the incidence 
of death, malformation, growth retardation,. o r .  functional 
deficit is not statistically greater than that of control subjects 
(Fig. 15.1). The threshold level oTexposure usually varies 
between less than one and up to two orders of magnitude 
below the teratogenic or embryopathic dose for drugs and 
chemicals that kill or malform one-half of the embryos. An 
exogenous teratogenic agent, therefore, has a no-effect dose 
compared with mutagens or carcinogens, which have a sto- 
chastic dose-response curve (Table 15.7, Fig. 15.1). The 
incidence and severity of malformations produced by all exoge- 
nous teratogenic agents that have been appropriately studied 
have exhibited threshold phenomena during organogenesis.' 
The threshold concept stems from the principle that manifes- 
tations of developmental toxicity occur because the processes 
of repair and regeneration have been overwhelmed by a par- 
ticular exposure to  a developmental toxicant. It does not pred- 
icate that no effect occurs at lower exposures, just that there is 
no deleterious or irreversible effect. 
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Table 15.5 Estimated outcome of pregnancy vs. time from conception. 
Time from conception Percent survival Percent loss during Last time for induction of selected malformationst 
to term* interval" 
Pre-implantation 
0-6 days 25 
Postimplantation 
7-13 days 5 5 
14-20 days 73 
3-5 weeks 79.5 
6-9 weeks 
10-13 weeks 
14-17 weeks 
18-21 weeks 
22-25 weeks 
26-29 weeks 
30-33 weeks 
34-37 weeks 
38+ weeks 
- 
22-23 days: cyclopia, sirenomelia, microtia 
26 days: anencephaly 
28 days: meningomyelocele 
34 days: transposition of great vessels 
36 days: cleft lip 
6 weeks: diaphragmatic hernia, rectal atresia, ventricular septa1 
defect, syndactyly 
9 weeks: cleft palate 
10 weeks: omphalocele; 12 weeks: hypospadias 
- 
- 
38+ weeks: CNS cell depletion 
"An estimated 50-70% of all human miscarriages occur in the first 3 weeks of gestati~n.'~.'~ 
+Modified from ref. 60. 
Table 15.6 Considerations that affect the interpretation of dose-response relationships. 
Concept Description Example 
Active metabolites Metabolites may be the proximate teratogen rather The metabolite phosphoramide mustard and acrolein may 
than the administered drug or chemical produce abnormal development resulting from the 
metabolism of cyclophosphamide 
Duration of exposure A chronic exposure to a prescribed drug can Anticonvulsant therapy; in contrast an acute exposure to the 
contribute to an increased teratogenic risk same drug may present little or no teratogenic risk 
Fat solubility Fat-soluble substances can produce fetal Polychlorinated biphenyls (PCBs). Etretinate may present a 
malformations for an extended period after the similar risk but the data are not conclusive 
last ingestion or exposure because they have an 
unusually long half-life 
Pharmacokinetics and metabolism of 
the drug or chemical 
Physiological alterations during pregnancy as well as the bio- 
conversion of compounds can significantly influence the 
teratogenic effects of drugs and chemicals by affecting absorp- 
tion, body distribution, the active form(s), and excretion of 
the compound. Tables 15.8 and 15.9 outline the pregnancy- 
related physiological alterations in the mother and fetus, 
respectively, that affect the pharrnacokinetics of drugs.4244 
Although other organs, including the placenta, can be 
involved in the metabolism of drugs or  chemicals, the major 
site of bioconversion of chemicals in vivo is likely to be the 
maternal liver. Placental P450-dependent monooxygenation of 
xenobiotics will occur at  low rates unless induced by com- 
pounds such as those found in tobacco smoke.45 However, the 
rodent embryo and yolk sac have been shown to possess func- 
tional P4SO-oxidative isozymes capable of converting pro- 
teratogens to  active metabolites during early ~ r ~ a n o g e n e s i s . ~ ~  
In addition, P4SO-independent bioactivation has been 
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Risk of intrauterine exDosure 
*' (teratogenesis) J;; 
m4 
Risk from preconception 
4 exposure (mutagenesis) 
Increasing dose of teratogen or 
mutagen 
Figure 15.1 Dose-response relationship of reproductive 
toxins comparing preconception and postconception risks. 
P 
Table 15.7 Stochastic and threshold dose-response relationships of diseases produced by environmental agents. 
Relationship Pathology Site Diseases Risk Definition 
Stochastic Damage to a single DNA Cancer, mutation Some risk exists at all The incidence of the 
phenomena cell may result in dosages; at low disease increases with 
disease exposures the risk is the dose but the severity 
below the and nature of the 
spontaneous risk disease remain the same 
Threshold Multicellular injury High variation in Malformation, No increased risk Both the severity and 
phenomena etiology, affecting growth retardation, below the threshold incidence of the disease 
many cell and death, chemical dose increase with dose 
organ processes toxicity, etc. 
Modified from ref. 73. 
Table 15.8 Pregnancy-related physiological alterations in the mother that affect the pharmacokinetics of drugs. 
Alteration Effect on drug pharmacokinetics 
Decreased gastrointestinal motility; increased intestinal Results in delayed absorption of drugs in the small intestine owing to increased 
transit time stomach retention and enhanced absorption of slowly absorbed drugs 
Decreased plasma albumin Alters the kinetics of compounds normally bound to albumin 
Renal elimination Generally increased but is influenced by body position later in pregnancy 
Increased plasma and extracellular fluid volumes Affects concentration-dependent transfer of compounds 
Inhibition of metabolic inactivation in the maternal liver Increases half-life of drug in plasma 
Variation in uterine blood flow May afect transfer across the placenta (although little is known concerning this) 
Based on concepts from refs 42-44. 
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Table 15.9 Pregnancy-related physiological alterations in the fetus that may affect the pharmacokinetics of drugs. 
Alteration Effect on drug pharmacokinetics 
Amount and distribution of fat Affects distribution of lipid-soluble drugs and chemicals 
Lower plasma protein concentrations Results in a higher concentration of unbound drug in the fetal circulation 
~unctional development of pharmacological Likely to proceed at  different rates in the various tissues of the developing fetus 
receptors 
Extent of amniotic fluid swallowing Drugs that are excreted by the fetal kidneys may be recycled through the fetus via swallowing 
of amniotic fluid 
Based on concepts from refs 42-44. 
suggested; for example, there is strong evidence that the rat 
embryo can reductively convert niridazole to an embryotoxic 
metabolite?' 
Bioconversion of xenobiotics has been shown to be important 
in their teratogenic activity. There is strong evidence that the 
reactive metabolites of cydophosphamide, 2-acetylaminofluo- 
rene, and nitroheterocycles (niridazole) are the proximate ter- 
atogens?* There is also experimental evidence suggesting that 
other chemicals undergo conversion to intermediates that have 
deleterious effects on embryonic development, for example, 
phenytoin, procarbazine, rifampicin, diethylstilbestrol, some 
benzhydrylpiperazine antihistamines, adriamycin, testosterone, 
benzo(a)pyrene, methoxyethanol, caffeine, and paraq~at .~ '*~* 
" Juchau4' has defined several experimental criteria to suggest 
that a suspected metabolite is responsible for the in uiuo terato- 
genic effects of a chemical or drug (Table 15.10). These criteria 
may explain why there are marked qualitative and quantitative 
differences in the species response to a teratogenic agent. 
Placental transport 
It has been suggested that the placental barrier is protective 
and that harmful substances do not reach the embryo; 
however, it is now clear that there is no "placental barrier" 
per se. The package inserts on many drugs state that "this drug 
'crosses the placental barrier"6 and the uninitiated may infer 
from this statement that this characteristic of a drug is both 
unusual and hazardous. However, most drugs and chemicals 
cross the placenta, and only selected proteins, whose actions 
are species specific, will cross the placental barrier in one 
species but not another. 
The role that the placenta plays in drug pharmacokinetics 
has been reviewed by Juchau and Rettie4' and involves: (1) 
transport; (2) the presence of receptor sites for a number of 
endogenous and xenobiotic compounds (P-adrenergic agents, 
glucocorticoids, epidermal growth factor, IgG-Fc, insulin, low- 
density lipoproteins, opiates, somatomedin, testosterone, 
transcobalamin 11, transferrin, folate, r e t i n ~ i d ) ; ~ ~  and (3) the 
bioconversion of xenobiotics. 
The factors which determine the ability of a drug or chem- 
ical to cross the placenta and reach the embryo include molec- 
ular weight, lipid affinity or solubility, polarity or degree of 
Table 15.10 Criteria to suggest that a suspected metabolite is 
responsible for the in vivo teratogenic effects of a drug or chemical. 
The chemical must be convertible to the intermediate 
The intermediate must be found in, or have access to, the tissue(s) 
affected 
The embryotoxic effect should increase with the concentration of 
the metabolite 
Inhibiting the conversion should reduce the embryotoxic effect of 
the agent 
Promoting the conversion should increase the embryotoxicity of the 
agent 
Inhibiting or promoting conversion should not alter the target 
tissues 
Inhibiting the conversion should increase the embryotoxicity of the 
agent 
Based on concepts from ref. 48. 
ionization, protein binding, and receptor mediation. Com- 
pounds with a low molecular weight and lipid affinity, non- 
polarity, and without protein-binding properties will cross the 
placenta rapidly and with ease. For example, ethyl alcohol 
reaches the embryo rapidly and in concentrations equal to or 
greater than the level in the mother. High-molecular-weight 
compounds like heparin (20 000 daltons) do  not cross the pla- 
centa readily and, therefore, during pregnancy, heparin is used 
instead of warfarin-like compounds for the treatment of 
hypercoagulation conditions. Rose Bengal does not cross the 
placenta at  all. In general, compounds with molecular weights 
of 1000 daltons or more do not readily cross the placenta, 
whereas those less than 600 daltons usually do; most drugs 
are 250-400 daltons and do  cross the pla~enta. '~ 
Genetic differences 
The genetic constitution of an organism is an important factor 
in the susceptibility of a species to a drug or chemical. More 
than 30 disorders of increased sensitivity to drug toxicity ,or 
effects in the human result from an inherited trait." Maternal 
and fetal genotypes determine the types of bioconversion 
route, the rate at  which bioconversions take place, and the 
extent to which a compound is metabolized. 
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however, negative animal studies do not guarantee that 
Environmental agents resulting in these agents are free from reproductive effects in humans. 
reproductive toxicity following exposure There are examples in which drug testing was negative in 
; during pregnancy animals (rat and mouse), but was teratogenic in the human (thalid~mide).~' Similarly, there are examples in which a drug 
Table 15.11 lists environmental agents that have resulted in 
reproductive toxicity and/or congenital malformations in 
humans. The list should not be used in isolation because many 
other parameters must be considered when analyzing repro- 
ductive risks in individual patients. Many of these agents rep- 
resent a very small risk while others may represent substantial 
risks; the risks will vary with the magnitude, timing, and 
length of exposure. Further information can be obtained from 
more extensive reviews or  summary articles. Table 15.12 
lists agents that have had concerns raised about their 
reproductive effects but which, after a careful and complete 
evaluation, have not been found to represent an 
increased reproductive r i ~ k . ~ ~ J ~ - "  References for the environ- 
mental agents can be found in review articles and texts on 
teratOgeneSiS.13~~8.24'38~51J~1 
Interpretation of animal study data 
for assessment of reproductive risks 
in humans 
As human studies are expensive and take years t o  complete, sci- 
entists have investigated the issue of whether appropriate animal 
models can be used to evaluate the reproductive and toxicolog- 
ical risks of environmental agents in humans (teratogenesis, 
growth retardation, pregnancy loss, stillbirth, and infertility). 
Whole animal teratology studies are helpful in raising con- 
cerns about the reproductive effects of drugs and chemicals; 
was teratogenic in an animal model but not in humans (diflu- 
nisal). Therefore, while chemicals and drugs can be evaluated 
for their toxic potential by utilizing in vivo animal studies and 
in vitro systems, it should be recognized that these testing pro- 
cedures are only one component in the process of evaluating 
the potential toxic risk of drugs and chemicals. Well- 
performed epidemiology studies still represent the best 
methodology for determining the risks and effects of environ- 
mental toxicants on humans. Indeed, most human teratogens 
have been discovered by alert physicians or during epidemiol- 
ogy studies, not animal studies.62 In vitro studies play an 
even less important role, although they are helpful in des- 
cribing the cellular or tissue-specific effects of drugs and 
chemicals. 
One useful aspect of animal studies is in corroborating 
findings reported in epidemiological studies. Attempts a t  risk 
assessment can be made by utilizing toxicokinetic data that 
have been obtained in an animal model, and exposure levels of 
the alleged toxicant and its metabolites that have been deter- 
mined in humans. Studies to elucidate whether the mechanism, 
of action of a drug or chemical in the animal model is the same 
as that in humans would further add to the toxicologist's 
ability to estimate human risks. This is not a simple process and 
explains why good-quality epidemiological studies are so  valu- 
able in determining human risks and toxicity. 
Clinicians are given little training in medical school and 
during residency training on  how to interpret animal 
toxicology studies. This is probably more true of reproductive 
Table 15.11 Proven human teratogens or embryotoxins: drugs, chemicals, milieu, and physical agents that have resulted in human congenital 
malformations. 
Reproductive toxin Alleged effects 
Aminopterin, methotrexate 
Androgens 
Angiotensin-converting enzyme 
(ACE) inhibitors 
Antituberculous therapy 
Caffeine 
Chorionic villus sampling (CVS) 
Cobalt in hematemic multivitamins 
Cocaine 
Corticosteroids 
Coumarin derivative 
Growth retardation, microcephaly, meningornyelocele mental retardation, hydrocephalus, and cleft palate 
Along with high doses of some male-derived progestins, can cause masculinization of the developing fetus 
Fetal hypotension syndrome in second and third trimester resulting in fetal kidney hypoperfusion and 
anuria, oligohydramnios, pulmonary hypoplasia, and cranial bone hypoplasia. No effect in the first 
trimester 
The drugs isoniazid (INH) and paraaminosalicylic acid (PAS) have an increased risk for some CNS 
abnormalities 
Moderate exposure not associated with birth defects; high exposures associated with an increased risk of 
abortion but data are inconsistent 
Vascular disruptive malformations, i.e., limb reduction defects 
Fetal goiter 
Very low incidence of vascular disruptive malformations, pregnancy loss 
High exposures administered systemically have a low risk for cleft palate in some epidemiological studies; 
howevet, this is not a consistent finding 
Exposure during early pregnancy can result in nasal hypoplasia, stippling of secondary epiphysis, and 
intrauterine growth retardation. Exposure in late pregnancy can result in CNS malformations as a 
result of bleeding 
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Table 15.11 Continued. 
Cyclophosphamide and other 
chemotherapeutic and 
immunosuppressive agents, 
e.g., cyclosporine, leflunomide 
Diethylstilbestrol 
Ethyl alcohol 
Ionizing radiation 
Insulin shock therapy 
Lithium therapy 
Minoxidil 
Methimazole 
Methylene blue intraamniotic 
instillation 
Misoprostol 
Penicillamine (D-penicillamine) 
Progestin therapy 
Propylthiouracil 
Radioactive isotopes 
Retinoids, systemic 
Retinoids, topical 
Streptomycin 
Sulfa drug and vitamin K 
Tetracycline 
Thalidomide 
Trimethoprim 
Vitamin A (retinal) 
Vitamin D" 
Warfarin (coumarin) 
- -  
Many chemotherapeutic agents used to treat cancer have a theoretical risk of producing fetal 
malformations, as most of these drugs are teratogenic in animals; however, the clinical data are not 
consistent. Many have not been shown to  be teratogenic but the numbers of cases in the studies are 
small; caution is the byword 
Genital abnormalities, adenosis, and clear cell adenocarcinoma of the vagina in adolescents. The risk of 
adenosis can be quite high; the risk of adenocarcinoma is 1:1000 to  1:10000 
Fetal alcohol syndrome (microcephaly, mental retardation, growth retardation, typical facial 
dysmorphogenesis, abnormal ears, and small palpebral fissures) 
A threshold greater than 20  rad (0.2 G y p a n  increase the risk of some fetal effects such as micocephaly 
or growth retardation. The threshold for mental retardation is higher 
Microcephaly and mental retardation 
Chronic use for the treatment of manic depressive illness has an increased risk for Ebstein's anomaly and 
other malformations, but the risk appears to  be very low 
Hirsutism in newborns (led to  the discovery of the hair growth-promoting properties of minoxidil) 
Aplasia cutis has been reported* 
Fetal intestinal atresia, hemolytic anemia, and jaundice in the neonatal period. This procedure is no 
longer utilized to  identify one rwin 
Low incidence of vascular disruptive phenomenon, such as limb reduction defects and Mobius syndrome, 
has been reported in pregnancies in which this drug was used to induce an abortion 
This drug results in the physical effects referred to  as lathyrism, the results of poisoning by the seeds of 
the genus Lathyrus. It causes collagen disruption, cutis laxa, and hyperflexibility of joints. The 
condition appears to  be reversible and the risk is low 
Very high doses of androgen hormone-derived progestins can produce masculinization. Many drugs with 
progestational activity do  not have masculinizing potential. None of these drugs has the potential for 
producing congenital malformations 
Along with other antithyroid medications can result in an infant born with a goiter 
Tissue- and organ-specific damage is dependent on the radioisotope element and distribution, i.e., high 
doses of l3'I administered to  a pregnant woman can cause fehl  thyroid hypoplasia after the 8th 
week of development 
Systemic retinoic acid, isotretinoin, and etretinate can result in an increased risk of CNS, cardio-aortic, 
ear, and clefting defects, microtia, anotia, thymic aplasia and other branchial arch and aortic arch 
abnormalities, and certain congenital heart malformations 
This is very unlikely to have teratogenic potential because teratogenic serum levels are not achieved from 
topical exposure 
Streptomycin and a group of ototoxic drugs can affect the eighth nerve and interfere with hearing; it is a 
relatively low-risk phenomenon. Children are even less sensitive to the ototoxic effects of these drugs 
than adults 
Hemolysis in some subpopulations of fetuses 
Bone and teeth staining 
Increased incidence of deafness, anotia, preaxial limb reduction defects, phocomelia, ventricular septa1 
defects, and GI atresias during susceptible period from the 22nd to the 36th day post conception 
This drug was frequently used to  treat urinary tract infections and has been linked to an increased 
incidence of neural tube defects. The risk is not high, but it is biologically plausible because of the 
drug's lowering effect on folic acid levels. This has also resulted in neurological symptoms in adults 
taking this drug 
Very high doses of vitamin A have been reported to produce the same malformations as those reported 
for the retinoids. Dosages sufficient to  produce birth defects would have to be in excess of 25000 to  
50000 units per day 
Large doses given in vitamin D prophylaxis are possibly involved in the etiology of supravalvular aortic 
stenosis, elfin facies, and mental retardation 
Exposure during early pregnancy can result in nasal hypoplasia, stippling of secondary epiphysis, and 
intrauterine growth retardation. Exposure in late pregnancy can result in CNS malformations as a 
, 
result of bleeding 
Anticonvulsants 
Carbamazepine Used in the reatment of convulsive disorders; increases the risk of facial dysrnorphology 
(Continued) 
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Table 15.11 Continued. 
Diphenylhydantoin 
Trimethadione and paramethadione 
Valproic acid 
Chemicals 
Carbon monoxide poisoning4 
Gasoline addiction embryopathy 
Lead 
Methyl mercury 
Polychlorinated biphenyls 
Toluene addiction embryopathy 
Embryonic and fetal infections 
Cytomegalovirus 
Herpes simpkx virus 
Human immunodeficiency 
virus ( H N )  
Parvovirus B19 infection 
Rubella virus 
Syphilis 
Toxoplasmosis 
Varicella zoster virus 
Venezuelan equine encephalitis 
Maternal disease states 
Corticosteroid-secreting 
endocrinopathy 
Iodine deficiency 
Intrauterine problems of 
constraint and vascular 
disruption 
Maternal androgen 
endocrinopathy (adrenal 
tumors) 
Maternal diabetes 
Folic acid insufficiency in the 
mother 
Maternal phenylketonuria 
Maternal starvation 
Tobacco smoking 
Zinc deficiency * 
'Controversial. 
'used in the treatment of convulsive disorders; increases the risk of fetal hydantoin syndrome, consisting 
of facial dysmorphology, cleft palate, ventricular septa1 defect (VSD), and growth and mental retardation 
Used in the treatment of convulsive disorders; increases the risk of characteristic facial dysmorphology, 
mental retardation, V-shaped eyebrows, low-set ears with anteriorly folded helix, high-arched palate, 
irregular teeth, CNS anomalies, and severe developmental delay 
Used in the treatment of convulsive disorders; increases the risk of spina bifida, facial dysmorphology, 
and autism 
CNS damage has been reported with very high exposures, but the risk appears to be low 
Facial dysmorphology, mental retardation 
Very high exposures can cause pregnancy loss; intrauterine teratogenesis is not established 
Causes Minamata disease consisting of cerebral palsy, microcephaly, mental retardation, blindness, and 
cerebellum hypoplasia. Endemics have occurred from adulteration of wheat with mercury-containing 
chemicals that are used to prevent grain spoilage. Present environmental levels of mercury are unlikely 
to represent a teratogenic risk, but reducing or limiting the consumption of carnivorous fish has been 
suggested in order not to exceed the Environmental Protection Agency's (EPA's) maximum permissible 
exposure (MPE), which is far below the toxic effects of mercury 
Poisoning has occurred from adulteration of food products (cola-colored babies, CNS effects, 
pigmentation of gums, nails, teeth and groin, hypoplastic deformed nails, intrauterine growth 
retardation, abnormal skull calcification). The threshold exposure has not been determined, but it is 
unlikely to be teratogenic at the present environmental exposures 
Facial dysmorphology, mental retardation 
Retinopathy, CNS calcification, microcephaly, mental retardation 
Fetal infection, liver disease, death 
Perinatal HIV infection 
Stillbirth, hydrops 
Deafness, congenital heart disease, microcephaly, cataracts, mental retardation 
Maculopapular rash, hepatosplenomegaly, deformed nails, osteochondritis at joints of extremities, 
.4 
congenital neurosyphilis, abnormal epiphyses, chorioretinitis 
Hydrocephaly, microphthalmia, chorioretinitis, mental retardation 
Skin and muscle defects, intrauterine growth retardation, limb reduction defects, CNS damage (very low 
increased risk) 
Hydranencephaly, microphthalmia, CNS destructive lesions, luxation of hip 
Mothers with Cushing's disease can have infants with hyperadrenocortism, but anatomical malformations 
do not appear to be increased 
Iodine deficiency can result in embryonic goiter and mental retardation 
Defects such as club feet, limb reduction, aplasia cutis, cranial asymmetry, external ear 
malformations, midline closure defects, cleft palate and muscle aplasia, cleft lip, omphalocele, and 
encephalocele. More common in multiple-birth pregnancies, pregnancies with anatomical defects of the 
uterus, placental emboli, and amniotic bands 
Masculinization 
Caudal and femoral hypoplasia, transposition of great vessels 
Increased incidence of neural tube defects (NTDs) 
Abortion, microcephaly, and mental retardation. Very high risk in untreated patients 
Intrauterine growth retardation, abortion, NTDs 
Abortion, intrauterine growth retardation, and stillbirth 
NTDs 
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Table 15.12 Agents erroneously alleged to have caused human malformations. 
Agent Alleged effect 
Doxylamine succinate (Bendectin) Alleged to cause numerous types of birth defects including limb reduction defects and heart malformations 
Diagnostic ultrasonography No significant hyperthermia, therefore no reproductive effects 
Electromagnetic fields (EMF) Alleged to cause abortion, cancer, and birth defects 
Progestational drugs Alleged to cause numerous types of congenital birth defects, including limb reduction defects and heart 
malformations 
~richloroeth~lene (TCE) Alleged to cause cardiac defects 
toxicology studies than of any other area of animal testing. For 
physicians the best source of information concerning animal 
testing comes from the drug package insert or the Physicians' 
Desk Reference (PDR).63 The PDR utilizes the Food and Drug 
Administration's (FDA's) classification of reproductive risks 
(categories A, B, C, D, and X), which is partly based on animal 
testing. Category A includes drugs that present no risk df 
reproductive effects. Category B, C and D drugs show increas- 
ing risks and category X includes drugs such as methotrexate, 
isotretinoin (Acutane), or thalidomide that should not be used 
in pregnant women or women of reproductive age who are not 
taking contraceptives. However, these categories are often 
more misleading than helpful. Teratologists, obstetricians, and 
other clinicians who counsel pregnant women have been very 
critical of the FDA's classificationh because it ignores the basic 
principles of teratology3 and the importance of modern phar- 
macokinetics in evaluating animal studies.29 In 1990, an article 
was published which indicated that of the 200 most frequently 
prescribed drugs, none represented a significant teratogenic 
risk.@ However, only a small proportion of rhese drugs was 
placed in category A by the FDA, the most important reason 
being the misapplication of animal testing results. When a new 
drug is marketed or a new environmental toxicant is discov- 
ered, however, often the only information that is available are 
the animal data. 
Evaluating animal studies to determine 
the potential risk in humans 
When utilizing animal data to assess the potential risk of a 
drug or chemical exposure in humans, it is important to crit- 
ically evaluate the studies using the basic principles of tera- 
tology guidelines (Table 15.2). As discussed previously, one of 
the most critical factors for consideration is the dose or mag- 
nitude of the exposure, and the concept of the threshold-dose 
effect for reproductive toxicants. A major shortcoming in 
many studies is the use of weight (mglkg) as a measure of dose, 
as dose comparisons based on mglkg doses are, at best, rough 
approximations. Instead, testing in animals could be improved 
if drugs and chemicals were administered to achieve pharma- 
cokineticalIy equivalent serum levels in the animal and human. 
Dose equ~valence between species can be accomplished only 
by performing pharmacokinetic studies, metabolic studies, 
and dose-response investigations in the human and the species 
being studied. Dose equivalence must also be determined for 
the drug-specific effects at  the cellular level, to account for 
species differences in the molecular targets of chemicals or 
drugs. An excellent example of the importance of the use of 
pharmacological, rather than weight-based, dose equivalenck 
in interpreting animal study data is illustrated by animal and 
epidemiological studies performed on lefl~nomide.~' 
Leflunomide is a relatively new drug (1998) which is used 
to treat rheumatoid arthritis. It contains a warning for repro- 
ductive effects (teratogenesis) and has been placed in category 
X. This classification was based on animal studies as there 
were no human data available at the.time of marketing. 
Leflunomide is a novel isoxazole immunomodulatory 
agent that has antiproliferative activity. It inhibits mitogen- 
stimulated proliferation of human peripheral blood mononu- 
clear cells (PBMCs) in a dose-dependent fashion. It has been 
demonstrated that the active metabolite binds to, and is a 
potent inhibitor of, dihydroorotate dehydrogenase 
(DHODH), an enzyme important for DNA synthesis in the de 
novo pyrimidine synthesis pathway. Together, these data 
suggest that at  serum concentrations achievable in patients, 
leflunomide inhibits de novo pyrimidine synthesis in activated 
lymphocytes and other rapidly dividing cell populations, 
resulting in reversible cell cycle arrest. 
In oral embryotoxicity and teratogenicity studies in rats and 
rabbits, leflunomide was embryotoxic (growth retarding, 
embryolethal, and teratogenic). The no-effect level for embry- 
otoxicity and teratogenicity in rats and rabbits was I mglkg 
body weight, which resulted in serum levels of 3.7 and 
4.1 pdmL respectively. In patients being treated with lefluno- 
mide, the active metabolite (the pyrimidine antagonist), is 
maintained at  a blood level of 40pglmL. The decision to label 
leflunomide as having a teratogenic risk was based on the fact 
that the human serum level was in the range of the teratogenic 
blood level in the animal models, and, therefore, the initial 
labeling was an appropriate precaution to prevent birth 
defects. 
After 4 years of treating rheumatoid arthritic patients with 
leflunomide there was no indication of an increase in 
teratogenesis in a very small group of pregnant patients who 
continued their pregnancy to term. The animal data were, 
therefore, reanalyzed as follows (referred to as the method 
of action (MOA) approach). The most likely mechanism 
of leflunomide teratogenicity is the suppression of DNA 
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synthesis and cell proliferation by the inhibition of pyrimidine 
synthesis. This is based on the assumption that, a t  the same 
serum levels of the active metabolite of leflunomide, suppres- 
sion of DNA synthesis, pyrimidine synthesis, and cell prolif- 
eration is equal in the rat, rabbit, and human. There would 
then be concurrence and the risks would be determined to be 
identical in all three species; this was the basis of the X-cate- 
gory labeling. However, in uitro studies on the active metabo- 
lite of leflunomide revealed that the rat was 40 and 328 times 
more sensitive to the suppression of DHODH and cell prolif- 
eration, respectively, than the human.32 This means that if 
enzyme suppression or antiproliferative activity is the mecha- 
nism (MOA) of teratogenicity in the rat, then the clinical use 
of leflunomide in pregnant women would probably not be ter- 
atogenic. It is important that this drug is subjected to ongoing 
epidemiological surveillance to confirm these findings. This is 
an example of how modern pharmacokinetic studies can 
improve risk assessment, making it easier to understand the 
epidemiological studies. 
Examples of in vivo animal studies 
In the past 2 years, many excellent in uiuo animal studies have 
been carried out. Two particular studies demonstrate the 
importance, differences, and the usefulness of animal studies 
as well as the difficulties inherent in drawing inferences from 
animal studies to describe human risk. Dam and c o a ~ t h o r s " ~  
used an in uiuo animal model to study the effect of chlorpyri- 
fos (CPF), an organophosphate insecticide whose domestic use 
has been curtailed in the USA because of concerns about its 
neurotoxicity, on gene expression. Newborn animals were 
injected subcutaneously with one of two different doses of 
CPF on postnatal days 1 4  or 11-14. Studies of the forebrain 
using molecular biological techniques revealed a significant 
elevation in one protein that persisted for 5 days after cessa- 
tion of the exposure regimen. This is an interesting study; 
however, the results are of little use in determining the human 
risks of CPF for the following reasons: 
1 CPF exposure in humans does not occur via subcutaneous 
injection but by ingestion or skin absorption of contaminated 
food or water. 
2 The serum concentration of CPF was not determined for 
the two different exposures used. 
3 There was no discussion of the range of levels of CPF that 
have occurred in human populations. 
4 The threshold dose and the no-observed adverse effect level 
(NOAEL) were not determined. 
5 The authors performed toxicogenomics without 
toxicokinetics. 
In contrast, the in uiuo study by Tyl and coauthors6%n the 
reproductive toxicity of dietary bisphenol in rats is considered 
to be a modern, animal toxicology study for the following 
reasons: 
.1 The bisphenol was placed in the diet ad libitum. 
2 There were seven exposure groups. 
3 The exposures were listed in ppm and mdkg. 
4 The range of exposures used was very' large: 0.001- 
500 mg/kg or a 500 000-fold range. 
5 The following were not affected a t  any of the lower expo- 
sures although some effects were observed in the 500mg/kg 
group: mating, fertility, gestational indices, ovarian primordial 
follicle counts, estrous cyclicity, precoital interval, gestational 
length, offspring sex ratios, postnatal survival, nipplelareolae 
retention in pre-weanling males, epididymal sperm number, 
motility, and morphology, daily sperm production, and effi- 
ciency of production 
6 The adult NOAEL was 5mg/kg/day and the reproductive 
NOAEL was SOmg/kg/day. There was a reduction in total 
body weight and some reduction in organ weight at  the higher 
exposures. 
To perform a risk analysis for bisphenol in the human 
population, some additional information is required that was 
not reported in this study but which is available in other 
studies. Yamada and coauthorsh7 obtained bisphenol exposure 
data in humans from the mother and amniotic fluid. The 
average concentration of bisphenol was 0.32ng/mL of serum, 
with a range of 0.0-1.6ng/mL, levels which appear to be 
far below the threshold exposure determined by Tyl and 
coauthors. However, Tyl and coauthors did not obtain the 
same pharmacokinetic data in the rat that Yamada and coau- 
thors reported in the human, and therefore the serum con- 
centration of bisphenol in the rat a t  the threshold exposure is 
not known. Furthermore, it is not known whether the metab- 
olism and effects of bisphenol are similar in the human and 
the rat. 
These studies"s6' on the risk analysis for bisphenol in the 
human population indicate the difficulties that can be faced in 
achieving an accurate and complete interpretation of the data. 
Combining such studies may appear to be a rare occurrence 
in the field of risk analysis; fortunately, however, it is occur- 
ring more often.6x 
In vitro testing 
In uitro tests can be utilized for preliminary screening proce- 
dures, and to study the mechanisms of teratogenesis and 
embryogenesis. However, in vitro studies will never be able to 
predict human teratogenic risks at  particular exposures 
without additional data obtained from whole animal and 
epidemiological s t ~ d i e s . ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~  In spite of the advances in in 
uitro and in uiuo testing for teratogenicity, human epidemio- 
logical surveillance by various methodologies is, and will con- 
tinue to be, our most powerful tool for discovering human 
reproductive toxins and teratogens. It may be difficult for 
experimental teratologists to accept the fact that alert physi- 
cians and scientists have been the most prominent contribu- 
tors to the discovery of the environmental causes of birth 
defects.lh 
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plete evaluation. This is also true if  a pregnant woman is 
The role of the physician in counseling exposed to a drug, chemical, or physical agent. ,As mentioned 
families regarding the etiology of - previously, only a small percentage of birth defects result from 
a child's congenital malformation exposure to prescribed drugs, chemicals, and physical 
 agent^'^.^^ (Table 15.3). Even when the drug is listed as a ter- 
The clinician must be cognizant of the fact that many patients 
believe that most congenital malformations are caused by 
a drug or medication taken during pregnancy. Counseling 
patients about reproductive risks requires a significant degree 
of knowledge and skill. Physicians must also realize that erro- 
neous counseling by inexperienced health professionals may 
result in nonmeritorious litigation.' 
Unfortunately, it has sometimes been assumed that if  a drug 
or chemical causes birth defects in an animal model or in vitro 
system at a high dose, then it has the potential for producing 
birth defects a t  any This may be reinforced by the 
fact that many teratology studies reported in the literature 
investigate the effects of several doses but do not determine 
the no-effect dose. 
Ignoring the basic tenets of teratology appears to occur most 
commonly in the evaluation of environmental toxic exposures 
when the exposure is very low or  unknown, and the agent has 
been reported to be teratogenic a t  a very high dose or a mater- 
nally toxic dose. In most instances, the actual population 
exposure is orders of magnitude helow the threshold dose, the 
doses that were used in animal studies, o r  those received 
during toxic exposures in the population. This has been 
the case with 2,4,5-trichlorophenoxyacetic acid (2,4,5-T), 
polychlorinated biphenyls (PCBs), lead, cadmium, arsenic, 
pesticides, herbicides, veterinary hormones, and industrial 
exposures. 
Unfortunately, there are exaniples where environmental dis- 
asters have been responsible for birth defects or pregnancy loss 
in exposed populations (methyl mercury in Japan, PCBs in the 
Far East, organic mercury in the Middle East, and lead poi- 
soning in the nineteenth and early twentieth centuries) and 
examples where teratogenic drugs have been inadvertently 
introduced (Table 15.1 1). Therefore, it is not possible to deter- 
mine whether a chemical or drug is safe or hazardous unless 
the magnitude of the exposure is known. 
Scholarly evaluation 
The physician should respond to a parent's query into the 
cause of a child's birth defect using the same professional and 
methodical approach that would be used in a differential diag- 
nosis for any clinical problem. Physicians have a protocol for 
evaluating complex clinical problems, for example, "fever of  
unknown origin," "failure to thrive," "congestive heart 
failure," or "respiratory distress." If a mother of a malformed 
infant had some type of exposure during pregnancy, for 
example, medication or a diagnostic radiological examination, 
the consulting physician should not support or suggest the 
possibility of a causal relationship before performing a com- 
atogen, to exert a teratogenic effect it has to be administered 
during the sensitive period of development for that drug, and 
above the threshold dose. Furthermore, the malformations in 
a child should be the same as the malformations in the ter- 
atogenic syndrome produced by that particular drug. It should 
be emphasized that in a recent analysis of the 200 most pre- 
scribed drugs in the USA, none were found to have measura- 
ble teratogenic potential.64 
After a complete examination of the child and a review of 
the genetic and teratology medical literature, the clinician 
must decide whether the child's malformations are genetic or 
result from exposure to an environmental toxin or agent. It 
may not be possible to definitively or presumptively conclude 
the etiology of the child's birth defects. This information must 
then be conveyed to the patient in an objective and compas- 
sionate manner. A similar situation exists if a pregnant woman 
has been exposed to a drug, chemical, or physical agent, as 
the mother will want to know the risk of the exposure to her 
unborn child. A formal approach is recommended to deter- 
mine whether a particular environmental drug, chemical or 
physical agent is a reproductive toxicant; this should include, 
where possible, data obtained from a number of investigative 
approaches (Table 15.13'") including: (1) epidemiological 
studies,"*'" (2) secular trend or ecological trend analysis, (3)  
animal reproductive studies,27-" (4)  dose-response relation- 
ships and pharmacokinetic, toxicokinetic, pharmacodynarnic, 
and toxicodynamic studies comparing human and animal 
metabolism, (5)  MOA studies that pertain specifically to 
the agent and include receptor affinity, cytotoxicity, genoto- 
7 5  7X..10.12 xicity, organ toxicity, neurotoxicity, etc.,-.-- (6) biological 
plausibility. 
Some typical analyses of the reproductive risks of doxy- 
lamine succinate (Bendectin), sex steroids, diagnostic ultra- 
sound, and electromagnetic fields demonstrate the usefulness 
of an organized approach to determine whether an environ- 
mental agent has been demonstrated to be a reproductive 
toxin.41,.5?-fl.6'l 
Clinical evaluation 
There are many articles and books that can assist the physi- 
cian with the evaluation of the medical literature and the clin- 
ical evaluation of the patient,'""R.24.'X.5',.56-"' although training 
programs d o  not usually prepare generalists to perform 
sophisticated genetic or teratology counseling. In addition to  
the ~ ~ s u a l  history and physical evaluation, the physician has to  
obtain information about the nature, magnitude, and timing 
of the exposure. The physical examination should include 
descriptive and quantitative inforn~ation about the physical 
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Table 15.13 Proof of developmental toxicity in humans. 
- 
Epidemiological studies 
Controlled epidemiological studies consistently demonstrate an increased incidence of a particular spectrum of embryonic and/or fetal effects in 
exposed human populations 
Seculnr trend data 
Secular trends demonstrate a positive relationship between the changing exposures to a common environmental agent in human populations 
and the incidence of a particular embryonic andlor fetal effect 
Animal developmental toxicity studies 
An.animal model that mimics the human developmental effect at clinically comparable exposures can be developed. Because mimicry may not 
occur in all animal species, animal models are more likely to be developed once there is good evidence for the embryotoxic effects reported 
in the human. Developmental toxicity studies in animals are indicative of a potential hazard in general rather than the potential for a specific 
adverse effect on the fetus when there are no human data on which to base the animal experinients 
Dose-response relationship (pharmacokinetics and toxicokinetics) 
Developmental toxicity in the human increases with dose (exposure), and the developmental toxicity in animals occurs at a dose that is 
pharmacokinetically (quantitatively) equivalent to the human exposure 
Biological plausibility 
The mechanisms of developmental toxicity are understood, and the effects are biologically plausible 
- - -- - - 
Modified from refs 20 and 74. 
characteristics of the child. While some growth measurements 
are routine, many measurements taken by specialized coun- 
selors are not part of the usual physical examination, e.g., 
palpebral fissure size, ear length, intercanthal distances, and 
total height-to-trunk ratio. Important physical variations in 
facial, hand, and foot structure as well as other anatomical 
structures may be suggestive of known syndromes, either 
teratological or genetic. 
Evaluation of the reproductive risk or cause of 
a child's malformation after an environmental 
exposure during pregnancy 
The vast majority of consultations involving pregnancy expo- 
sures conclude that the exposure does not change the repro- 
ductive risks for that pregnancy. In many instances, the 
information that is available is so vague that the counselor 
cannot reach a definitive conclusion about the magnitude of 
the risk. The following information is necessary to evaluate 
any risk: 
1 What was the nature of the exposure? 
2 Is the exposure agent identifiable? If so, has it been defini- 
tively identified as a reproductive toxin with a recognized 
range of malformations or  other reproductive effects? 
3 At what stage during embryonic and fetal development did 
the exposure occur? 
4 If the agent is known to produce reproductive toxic effects, 
was the exposure above or  below the threshold for these 
effects? 
5 Were there other significant environmental exposures or  
medical pmblems during the pregnancy? 
230 
6 Is this a wanted pregnancy or is the family ambivalent about 
carrying this baby to term? 
7 What is the medical and reproductive history of the mother 
with regard to prior pregnancies and the reproductive history 
of the family lineage? 
After obtaining this information, the counselor is able 
to provide the family with an estimate of the reproductive 
risks of the exposure. Some examples of consultations that 
have been referred to our clinical teratology service are listed 
below. 
Patient 1 
A 34-year-old pregnant laboratory worker dropped and broke 
a reaction vessel containing a mixture of chemical reagents. 
She proceeded to clean the floor with paper towels and later 
became concerned about the potential harmful effects of the 
exposure. This was a planned, wanted pregnancy; she was in 
the sixth week of pregnancy and, therefore, the embryo was 
in the period of early organogenesis. The chemicals in the spill 
were tetrahydrofuran (70%),  pyridine (20%), and iodine 
(1%). It was not possible to quantitatively estimate the expo- 
sure to these agents, but the laboratory worker experienced 
no symptoms from the exposure. There have been no epi- 
demiological studies of tetrahydrofuran and pyridine in preg- 
nant women but iodine has been shown to interfere with fetal 
thyroid development; in this situation, however, the exposure 
would have been inconsequential because, at this stage of 
pregnancy, the thyroid is not yet present. No other exposure 
to reproductive toxins occurred in this pregnancy and the 
family history for congenital malformations was negative. The 
woman was advised that it would be very unlikely that her 
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teratogenic risk woi~ld be increased because the exposures to 
the embryo would be extremely low. She was told that she still 
faced the background risks for birth defects and miscarriage 
and, therefore, her reproductive risks would be the same as 
tl?at of the general population (Table 15.1). 
Patient 2 
A 26-yeai-old pregnant woman was in an automobile accident 
in the 10th week of her pregnancy and sustained a severe con- 
cussion. Although she did not convulse post injury, the treat- 
ing neurosurgeon prescribed 300mg of diphenylhydantoin 
during her first 24h  in hospital. Fortunately, she recovered 
from the injury without any sequelae but her primary physi- 
cian was concerned that she had received an anticonvulsant 
associated with a teratogenic syndrbme. No other exposure to 
reprocluctive toxins occurred in this pregnancy and the family 
history for congenital malformations was negative, except for 
an uncle with neurofibromatosis. The primary physician 
requested a consultation with regard to the teratogenic risk. 
While diphenylhydantoin administered chronically through- 
out pregnancy has been associated with a low incidence of 
characteristic facial dysmorphogenesis, reduced mentation, 
cleft palate, and digital hypoplasia, there are no data to indi- 
cate that 24 h of therapy would cause any of these features. In 
addition, the development of the lip and palate are complete 
by the 10th week of pregnancy. ?;his was a wanted pregnancy 
and the mother chose to continue her pregnancy; she deliv- 
ered a normal 3370-g boy at term. 
Patient 3 
A 25-~ear-old woman was seen in the emergency service of 
her local hospital with nausea, vomiting, and diarrhea, on 
return from a cruise on which a number of the passengers 
became il l  with similar symptoms. The emergency-ward physi- 
cian ordered a pregnancy test followed by a flat-plate radi- 
ograph of the abdomen as there was evidence of peritoneal 
irritation; however, both of these tests were negative. One 
week later she missed her menstrual period and a subsequent 
pregnancy test was positive. Her obstetrician was concerned 
because she had been exposed to a radiological examination 
at a time when she was pregnant; he referred the patient for 
counseling after obtaining an ultrasound that indicated that 
the embryo was approximately 7 days post conception a t  the 
time of the examination. The patient advised the counselor 
that she was ambivalent about the pregnancy because of the 
"dangers" of the X-rays to her embryo. The estimated expo- 
sure to the embryo was less than 500 mrad (O.OOSSv), an 
exposure that is far below that known to affect the develop- 
ing embryo. Also, the embryo was exposed during the first 2 
weeks post conception, a time that is less likely to increase the 
risk of teratogenesis, even at  much higher  exposure^.'^^" After 
an evaluation of the family history and after receiving coun- 
seling about the risks of the radiological examination, the 
woman decided to continue the pregnancy; she delivered a 
normal 3150-g baby. 
Evaluation of the cause of a child's 
congenital malformations: unknown, genetic, 
or environmental 
Patient 4 
The mother of a 30-year-old man born in the Azores in 1960 
with a congenital absence of the right leg below the ltnee had 
pursued compensation for her son because she was certain that 
she must have received thalidomide during her pregnancy.4 
The German manilfactilrer of thalidomide refused compensa- 
tion, claiming that thalidomide had never been distributed in 
the Azores. The mother fervently believed that thalidomide 
was responsible for her son's malformations and asked for my 
opinion; she sent me the radiograph studies of his hips and 
l e ~ s  and his complete evaluation performed at the local hos- 
pital in the Azores. He had none of the other stigmata of 
thalidomide embryopathy (preaxial limb defects, phoconielia, 
facial hemangioma, ear malformations, deafness, crocodile 
tears, ventricular septa1 defect, intestinal or gallbladder 
atresia, and kidney malformations) and, most importantly, his 
limb n~alformations were not of the thalidoniide type; he had 
a unilateral congenital amputation with no digital remnants 
at the end of the limb, his pelvic girdle was completely normal, 
and his limb defect involved only one leg with the other leg 
being normal. In this particular case, the man had a congeni- 
tal amputation probably resulting from vascular disruption of 
an unknown etiology (known causes of vascular disruptive 
malformations are cocaine, misoprostol and chorionic villous 
sampling). It is difficult to determine whether any amount of 
appropriate counseling will give closure to this mother. 
Patient 5 
The family of a malformed boy claimed that the antinausea 
medication doxylamine succinate (Bendectin),s2"'-7' taken by 
the mother during pregnancy, was responsible for the child's 
congenital limb reduction defects. Bendectin was taken after 
the period of limb organogenesis; however, some limb 111al- 
formations can be produced by teratogens after this time. The 
boy's malformation was the classical split-hand, split-foot 
syndrome, which is donlinantly inherited; it was unaccompa- 
nied by any other dysmorphogenetic effects. Although signif- 
icant number of cases of this syndrome result from a new 
mucation, neither parent manifested the malformation and this 
suggested that a new mutation had occurred in the sex cells 
of one of the parents. Therefore, the risk of this malformation 
occurring in the offspring of this boy would be 50%. It was 
concluded that Bendectin was not responsible for this child's 
malformation; however, in spite of the obvious genetic etiol- 
ogy of the birth defect, a legal suit was filed. A jury decided 
for the defendant, namely, that Bendectin was not responsible 
for the child's malformation. 
Patient 6 
A woman visited a hospital emergency ward with severe lower 
abdominal pain; as she had had a previous ectopic pregnancy 
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that necessitated the removal of her ovary and Fallopian tube, 
she was seen by an obstetrical resident. A pregnancy test was 
positive and she returned to the obstetrical clinic a week later 
when her chorionic gonadotropin level was retested. It had 
- not changed from its previous level and, without performing 
I '  
an ultrasound, a diagnosis of ectopic pregnancy was made; in 
order to preserve the patient's reproductive potential, it was 
decided to treat the ectopic pregnancy with methotrexate 
rather than remove the remaining fallopian tube and ovary. 
However, following the administration of methotrexate, a 
laboratory report was received which indicated that the 
gonadotropin level had increased fivefold, and a subsequent 
ultrasound revealed a normally implanted embryo; the labo- 
ratory report received earlier in the day was found to be a 
copy of the original report performed a week earlier. The 
mother was counseled that the baby was a t  an increased 
risk of having congenital malformations because of the expo- 
sure to methotrexate; however, she refused to abort the preg- 
nancy. The obstetrical departmelit therefore offered to 
provide care for the pregnancy and delivery that included a 
number of ultrasound examinations. At 28 weeks, the patient 
went into labor and delivered a premature liveborn infant, and 
during infancy, the child was diagnosed with hydrocephalus, 
developmental delay, and spastic cerebral symptomatology. 
The family filed a lawsuit against the doctors and hospital and 
I was asked to evaluate the allegation that the abnormalities 
in the child were due to the administration of methotrexate. 
Methotrexate has been reported to cause growth retardation, 
microcephaly, developmental delay, and hydrocephalus, but 
not prematurity. The clinical care provided by the resident 
doctor was unfortunate; however, the provision of care by the 
obstetrical department turned out to be fortunate for the 
defendants in this case. A review of the records revealed two 
important findings: first, an ultrasound examination taken a 
week before the premature delivery revealed that there was no 
evidence of hydrocephalus and, second, the birthweight 
was appropriate for the gestational stage. Therefore, the expo- 
sure to methotrexate was not responsible for the serious 
problems in this infant; the hydrocephalus and neurological 
symptoms resulted from a central nervous system (CNS) 
bleed in the postnatal period as a complication of the 
prematurity. 
These examples show that it is not a simple process to 
determine the reproductive risks of an exposure during preg- 
nancy or to determine the etiology of a child's congenital mal- 
formations. It requires careful analysis of the medical and 
scientific literature on the reproductive toxic effects of exoge- 
nous agents in humans and animals, as well as an evaluation 
of the exposure and biological plausibility of an increased 
risk or a causal connection between the exposure and a 
child's congenital malformation. It also involves a careful 
physical examination, and a review of the scientific literature 
regarding the genetic and environmental causes of the mal- 
formations in question. Abridged counseling, based on super- 
ficial and incomplete analyses, is a disservice to the families 
.involved. 
Conclusion 
Approximately 10% of human malformations are due to 
environmental causes and fewer than 1% are related to 
prescription drug exposure, chemicals, or radiation. How- 
ever, malformations caused by drugs and other therapeutic 
agents are important because these exposures may be pre- 
ventable. Advances in animal research and epidemiology have 
enabled scientists to gain a better understanding of the mech- 
anisms of teratogenesis. 
Concerns about environmental chemicals and physical 
agents are clearly justified because, in most cases, not enough 
information is available on the potentially differential effects 
on the fetus and child. Such information, for example, the 
population exposure and the NOAEL, can only be obtained 
from high-quality human and animal toxicology and epi- 
demiological studies which include toxicokinetic and toxico- 
dynamic data and, therefore, it is essential that we expand 
our research programs in these areas. Ecological studies that 
do  not measure exposures in the human population are 
more confusing than helpful in determining human risks, and 
study~ng exposures to groups of agents, e.g., solvents and 
pesticides, does not allow a risk assessment for individual 
toxicants. 
All chemicals and drugs have the potential for develop- 
mental toxicity if the exposure is high enough; it would there- 
fore be beneficial if humans were not exposed to chemicals in 
the workplace or home, or if chemicals were not dispersed into 
the environment. To address this problem now, and in the 
future, an extensive program of monitoring, reducing, and , 
eliminating the delivery of chemicals to the environment and 
the exposure of populations to chemicals is needed. Introduc- 
ing or banning chemicals that expose the human population 
is an extremely difficult task that needs to be carefully planned 
on the basis of risks and benefits. 
DEVELOPMENTAL TOXICOLOGY, DRUGS, AND FETAL TERATOGENESIS 
I Key points 
1 0  Teratog 
wherea 
stochast~c aose-response cu 
11 Physiol 
b' ~oconi  lfluence 
the tera,,,,,~,~ c r l c c r o  ul ulusr. auu c u c r u ~ c a a u  uy 
affecting absorpti 
and excretion of 
1 Severe congenital malformations (including those birth 
defects that cause death, hospitalization, and mental 
retardation, and those that necessitate significant or 
repeated surgical procedures, are disfiguring, or 
interfere with physical performance) occur in 3 %  of all 
births. 
;ens follov 
s mutagen 
'. I 
v a thresh( 
s and carc 
:sponse cu 
nd to follc 
ogical alte 
rersion of 
,+,-."a":, 
!rations in 
compounc 
'Fa,.'." I\ C A * 
and the 
~ificantly i~ 
+am;,-nlc h
pregnancy 
is can sign 
,,"a ""A ,t 
2 Only a small percentage of birth defects are due to 
prescribed drugs, chemicals, and physical agents. Even 
when a drug is listed as a teratogen, it has to be 
administered during the sensitive period of 
development for that drug, and above the threshold 
dose for producing teratogenesis. Environmental causes 
account for approximately 10% of human birth 
malformations, and fewer than 1 %  of all human 
. malformations are related to prescription drug 
exposure, chemicals, or radiation. 
Ion, body I 
the compc 
J - - . . . 
distributio 
bund. 
onse relati 
n, active f~ 
12 Interpretation of aose-respl 
teratog~ 
metabo 
teratogl 
chemical, the duratlon or the exposure (cnronlc versus 
acute), and the fa y of the at 
1 3  The role that the days in dr 
pharmacokinetics I U V W V G ~  transport, ~ L L J L ~ ~ L L !  of 
recepto :ndogenous and xenl 
cornpol lversion of xenobiot 
onships fo 
ens must t 
llites, whe~  
en rather I 
, .  . 
,ake into a ccount the 
tes might 
dministere 
: active 
be the prc 
d drug or 
I ,  . 
n metaboli 
ihan the ac 
. . - l  
~t solubilir 
placenta I 
, :-..-I ..-,. 
3 The etiology of congenital malformations can be 
divided into three categories: unknown (65-75%), 
genetic (15-25%), and environmental (10%). 
rs for a nt 
~nds ,  and 
lmber of e 
the biocor 
a .  ,- 
~b io t i c  
ics. 
1 4  The genetlc constltutlon or an individual is an 
important factor 
species to a drug 
1 5  Animal teratolog 
concerns about the reproduct~ve ettects ot drug 
chemicals, but negative animal studie 
that these agents are free from reproc 
4 Reproductive problems alarm the public, press, and 
some scientists, to a greater degree than most other 
d' ~seases. 
that affect 
or chemic 
.s the suscc 
al. 
sptibility c 
y studies a Ire helpful 
. .. 
in raising 
. . 5 Physicians must recognize the consequences of 
providing erroneous reproductive risks to pregnant 
women exposed to drugs and chemicals during 
pregnancy, or of alleging that a child's malformations 
are caused by an environmental agent without 
performing a complete and scholarly evaluation. 
s and 
,uarantee 
ects. 
.I. L^^L 
s do  not g 
juctive effi 
--------A 1 6  Well-performed epidemioloev studies r e v r c b c r l L  
methodology for determinil 
effects of environmental to: 
LLlC UCLL 
nd the 
cme nf 
", 
ng the hur 
xicants. 
a .  
nan risk a 
. .  . 
6 Labeling an environmental exposure as teratogenic is 
inappropriate unless one characterizes the exposure 
with regard to the dose, route of exposure, and stage 
of pregnancy when the exposure occurred. 
7 The application of the basic scientific principles of 
teratology is extremely important in evaluating studies 
.. on the reproductive effects of an environmental agent. 
These principles include the following criteria: exposure 
o teratogens follows a toxicological dose-response 
urve; the embryonic stage at which exposure occurs 
letermines what effects (if any) a teratogen has; most 
I eratogens have a confined group of congenital malformations (syndrome of agent's effects) and; no  teratogen can produce every type of malformation. 
17 In vitro tests can be used to study the mechanl. 
teratogenesis and embryogenesis, and for prelin 
screening procedures. However, in vitro studies 
predict human teratogenic risks at particular ex 
without the bene 
animal studies ar 
1 8  The clinician mu 
patients believe tnat most congenlcal malrormarlons are 
caused by a drug 
pregnancy. 
1 9  Ignoring the basic LcrIr;La v L  r r r a ~ v ~ v ~ y  appears to occur 
most commonly in the evaluation of environme 
exposures when the exposure was very low or 
unknown and the agent has been reported to b 
teratog 
dose, 
20 The ev; 
should (when posslme) use aata ootalnea rrom 
investigative approaches including: (1) epidemiological 
studies, (2) secular trend analysis, (3) animal 
reproductive studies, (4) dose-response relationshios. 
(5) mec )f action (MOA) stul 
specific : agent and include r 
cytotox )toxicity, organ toxic 
neurotoxlclcy, and (6) biologica! p ~ a ~ ~ l ~ l l l t y .  
-*.a- -- 
ninary 
cannot 
:posures 
from who1 
udies. 
fit of data 
~d epidemi 
st be cogn 
obtained 
ological st 
le 
: many 
I .  
izant of. th 
. I 
le fact that 
I P  . 
or medic: ation taker 
: cn*n*rrlrrn 
I during 
- 
8 The risk of morphological anomalies or intrauterine 
death resulting from exposure to a developmental 
toxicant varies depending on the dose and the 
embryonic or fetal stage at which exposure occurs. 
ternally tc enic at a F 
aluation o 
, . 
rery ,high c lose or ma 
f the toxic 
., 3 , 
;s .and che 
. , ,  
micals 
9 The threshold dose for an environmental toxicant is the 
dose below which the incidence of death, 
malformation, growth retardation, or functional deficit 
is not greater than that of control subjects. The severity 
. and incidence of malformations produced by every 
exogenous agent that has been appropriately studied 
have exhibited threshold phenomena during 
organogenesis. 
:hanisms c 
ally to the 
:icity, genc 
9 .  
dies that p 
eceptor af 
:ity, and 
,, .,. 
L ,  
lertain 
finity, 
CHAPTER 1 5  
References 
1 Brent ItL. Medicolegal aspects of teratology. ] Pediatr 1967;71: 
288-298. 
2 Brent RL. Litigation:produced pain, disease and suffering: an expe- 
rience with congenital malformation lawsuits. Teratology 1977; 
16:l-14. 
3 Brent RL. Utilization of developmental basic science principles in 
the evaluation of reproductive risks from pre- and postconception 
environmental radiation exposures. Teratology 1999;59:182-204. 
4 Brent RL, Holmes L. Clinical and basic science lessons from the 
thalidomide tragedy: what have we learned about the causes of 
limb defects? Teratology 1988;38:241-251. 
5 Brent RL. The irresponsible expert witness: a failure of biomedical 
graduate eclr~cation and professional accountability. Pediatrics 
1982;70:754-762. 
6 Brent RL. Drugs and pregnancy: are the insert warnings too dire? 
Contemp Oh-Gyn 1982;20:42-49. 
7 Wilson J. Environment and birth defects. New York: Academic 
Press, 1973. 
8 Brent RL. Environmental factors: miscellaneous. In: Brent RL, 
Harris M, eds. Prevention of embryonic, fetal and perinatal 
disease. Bethesda, MD: John E. Fogarty International Center for 
Aduanced Study in the Health Sciences, NIH; 1976:211. 
9 Heinonen 0, Slone D, Shapiro S. Birth defects and drugs in preg- 
nancy. Littleton, MA: Publishing Sciences Group, 1977. 
10 Brent RL, Beckman D. Environmental teratogens. New York: 
New York Academy of Medicine, 1990. 
11  Beckman D, Fawcett L, Brent RL. Developmental toxicity. In: 
Massaro E, ed. Handbook of human toxicology. New York: CRC 
Press; 1997:1007-1084. 
12 Brent RL, Beckman D. Prescribed drugs, therapeutic agents, and 
fetal teratogenesis. In: Reece E, Hobbins J, eds. Medicine of the 
fetus and mother, 2nd edn. Philadelphia, PA: Lippincott-Raven 
Publishers; 1999:289-313. 
13 Aase J. Diagnostic dysmorphology. New York: Plenum Medical 
Book Co., 1990. 
14 Beckman D, Brent RL. Fetal effects of prescribed and self- 
administered drugs during the second and third trimester. In: 
Avery G, Fletcher M, MacDonald M, eds. Neonatology: patho- 
physiology and treatment, 4th edn. Philadelphia, PA: JB Lippin- 
cott Co.; 1994,:197-206. 
15 Brent RL. What is the relationship between birth defects and preg- 
nancy bleeding? New perspectives provided by the NICHD work- 
shop dealing with the association of chorionic villous sampling 
and the occurrence of limb reduction defects. Teratology 1993;48: 
93-95. 
16 Brent RL, Beckman D. Teratogens: an overview. In: Knobil E, Neill 
J, eds. Encyclopedia of reproduction. New York: Academic Press; 
1999:735-750. 
17  Graham JJ, Jones K, Brent RL. Contribution of clinical teratolo- 
gists and geneticists to the evaluation of the etiology of congeni- 
tal malformations alleged to be caused by environmental agents, 
ionizing radiation, electromagnetic fields, microwaves, radionu- 
clides, and ultrasound. Teratology 1999;59:307-313. 
18 Jones K. Smith's recognizable pattern of human malforn~atiotrs, 
5th edn. Philadelphia, PA: WB Sat~nders Co., 1994. 
19  Brent RL, Beckman D. Angiotensin-converting enzyme inhibitors, 
an embryopathic class of drugs with unique properties: informa- 
tion for clinical teratology councilors. Teratology 1991;43:543- 
545. 
20 Brent RL. Methods of evaluating the alleged teratogenicity of envi- 
ronmental agents. In: Sever J, Brent RI., eds. Tcratoyen update: 
environmentally induced birth defect risks. New York: Alan R 
Liss; 1986:199-201. 
21 Brent RL. Effects ant1 risks of medically administered isotopes to 
the developing embryo. In: Fabro S, Scialli A, eds. Drugand chem- 
ical action in pregnancy. New York: Marcel Dekker; 1986:427- 
439. 
22 Brent 1tL. Radiation teratogenesis. Teratology 1980;21:281- 
298. 
23 Brent RL, Beckman D. Developmental effects following radiation 
of embryonic and fetal exposure to x-ray and isotopes: counsel- 
ing the pregnant and nonpregnant patient about these risks. In: 
Hendee W, Edwards F, eds. Health effects of low levels exposure 
to ionizing radiation. Bristol & Philadelphia: Institute of Physics 
Publishing; 1996:169-213. 
24 Online Mendelian Inheritance in Man, OMIM'''M. McKusick- 
Nathans Institute for Genetic Medicine, Johns Hopkins University 
(Baltimore, MD) and National Center for Biotechnology Infor- 
mation, National Library of Medicine (Bethesda, MD), 2000. 
World Wide Web URL: http:l/www.ncbi.nlm.nih.govlomiml 
25 Brent RL. Evaluating rhe alleged teratogenicity of environmental 
agents. In: Brent RL, Beckman D, eds. Clinics in perinatology. 
Philadelphia, PA: WB Saunders; 1986:609-613. 
26 Brent RL. Protecting the public from teratogenic and mutagenic 
hazards. ] Clin Pharmacol 1972;12:61-70. 
27 Brent RL. Drug testing in animals for teratogenic effects: thalido- 
mide in the pregnant rat. J Pediatr 1964;64:762-770. 
28 Brent RL. The prediction of human diseases from laboratory and 
animal tests for teratogenicity, carcinogenicity, and mutagenicity. 
In: Lasagna L, ed. Controversies in therapeutics. Philadelphia, PA: 
WB Saunders; 1980:134-150. , 
29 Brent RL. Predicting teratogenic and reproductive risks in humans 
from exposure to various environmental agents using in uitro 
techniques and in uivo animal studies. Cong Anomalies 1988; 
28(Suppl.):41-55. 
30 Christian M, Brent RL. Teratogen update: evaluation of the repro- 
ductive and developmental risks of caffeine. Teratology 2001;64: 
51-78. 
31 Brent RL. Scientific frontiers in developmental toxicology and risk 
assessment (Review). Teratology 2002;65:88-96. 
32 Brent RL. Teratogen update: reproductive risks of leflunomide 
(Avara). A parimidine synthesis inhibitor: counseling -women 
lacking leflunomide before or during pregnancy and men taking 
leflunomide who are contemplating fathering a child. Teratology 
2001;63:106-112. 
33 Carter C. Genetics of common single malformations. Br Med I3ull 
1976;32:21-26. 
34 Fraser The multifactoriallthreshold concepr: uses and misuses. 
Teratology 1976;14:267-280. 
35 Boue J, Boue A, Lazar P. Retrospective and prospective epidemi- 
ological studies of 1500 karyotyped spontaneous abortions. Ter- 
atology 1975;12:11-26. 
36 Hertig A. The overall problem in man. In: Benirschke K, ed. Cotn- 
parative aspects of reproductive failure. Berlin: Springer-Verlag; 
1967:l l .  
37 Simpson J. Genes, chromosomes and reproductive failure. Fertil 
Steril 1980;33:107-116. 
38 Sever J. Infections in pregnancy: highlights from the collective peri- 
natal project. Teratology 1982;2.5:227-237. 
39 Briggs M, Briggs M. Sex hormone exposure during pregnancy and 
malformations. Adv Steroid Diocbem 1'l:armacol 1979;7:51-89. 
DEVELOPMENTAL TOXICOLOGY, DRUGS, AND FETAL TERATOGENESIS 
$0 Hochner-Celnikier D, Marandici A, lohan F, Monder C. Estrogen 
and progesterone receptors in the organs of prenatal Cynomolgus 
monkey and laboratory mouse. Biol Reprod 1986;35:633-640, 
$1 Wilson J, Brent RL. Are female sex hormones teratogenic? Am j 
Obstet Gynecol 1981;141:567-580. 
$2 Jackson M. Drug absorption. In: Fabro S, Scialli A, eds. Drug and 
chemical action in pregnancy: pharmacologic and  toxicologic^ 
principles. New York: Marcel Dekker; 1986:lS. 
43 Mattison D. Physiologic variations in pharmacokinetics during 
pregnancy. In: Fabro S, Scialli A, eds. Drug and chemical action 
during pregnancy: pharmacologic and toxicologic principles. New 
York: Marcel Dekker; 1986:37-102. 
44 Sonawane B, Yaffe S. Physiologic disposition of drugs in the fetus 
and newborn. In: Fabro S, Scialli A, eds. Drug and chemicalaction 
in pregnancy: pharmacologic and toxicologic principles. New 
York: Marcel Dekker; 1986:103. 
45 Juchau M, Rettie A. The metabolic role of the placenta. In: Fabro 
S, Scialli A, eds. Drug and chemical action in pregnancy: phar- 
macologic and toxicologic principles. New York: Marcel Dekker; 
1986:153-169. 
46 Yang H, Namkung M, Juchau M. Cytochrome P45O-dependent 
biotransformation of a series of phenoxazone ethers in the ra,t con-. 
ceptus during early organogenesis: evidence for multiple P450 
isozymes. Mol Phamacol1988;34:67-73. 
47 Fantel A, Person R, Juchau M. Niridazole metabolism by rat 
embryos in vitro. Teratology 1988;37:213-221. 
48 Juchau M. Bioactivation in chemical teratogenesis. Annu Rev 
Pharmacol Toxicol 1989;29:165-187. 
49 Miller R. Placental transfer and function: the interface for drugs 
and chemicals in the conceptus. In: Fabro S, Scialli A, eds. Drug 
and chemical action in pregnancy: phamacologic and toxicologic 
principles. New York: Marcel Dekker; 1986:123. 
50 Mirkin B. Maternal and fetal distribution of drugs in pregnancy. 
Clin Pharmacol Ther 1973;14:643-647. 
51 McKusic V. Medelian inheritance in man: catalogs of au- 
tosomal dominant, autosomal recessive, and x-linked phenotypes, 
8th edn. Baltimore, MD: Johns Hopkins University Press, 1988. 
52 Brent RL. Bendectin: review of the medical literature of a com- 
prehensively studied human non-teratogen and the most prevalent 
tortigen-litigen. Reprod Toxicol 1995;9:337-349. 
53 Brent RL. Review of the scientific literature pertaining to the 
reproductive toxicity of bendectin. In: Faigman D, Kaye D, Saks 
M, et al., eds. Modern scientific evidence: the law and science of 
expert testimony. St. Paul, MN: West Publishing Group; 1997: 
373-393. 
54 Brent RL. Microwaves and ultrasound. In: Queenan J, Hobbins J, 
eds. Protocols for high risk pregnancies, 3rd edn. Cambridge: 
Blackwell Scientific; 1995:37-43. 
55 Brent RL, Gordon W, Bennett W, Beckman D. Reproductive and 
teratogenic effects of electromagnetic fields. Reprod Toxicol 
1993;7:535-580. 
56 Friedman J, Polifka J. TERIS. The teratogen information system. 
Seattle, WA: University of Washington, 1999. 
57 Scialli A, Lione A, Padget GKB. Reproductive effects of chemical, 
physical and biologic agents. Baltimore, MD: Johns Hopkins Uni- 
versity Press, 1995. 
58 Sever J, Brent RL. Teratogen update: environmentally induced 
birth defect risks. New York: Alan R Liss, 1986. 
59 Sheperd T. Catalogue of teratogenic agents, 8th edn. Baltimore, 
MD: Johns Hopkins University Press, 1995. 
60 Schardein J. Chemically induced birth defects. New York: Marcel 
Dekker, 1993. 
61 Briggs G, Freeman R, Yaffe S. Drugs in pregnancy and lactation, 
3rd edn. Baltimore, MD: Williams and Wilkins, 1990. 
62 Miller R. How environmental hazards have been discovered: car- 
cinogens, teratogens, neurotoxins, and others. Pediatrics 2004; 
113:945-951. 
63 Physicians Desk Reference, 57th edn: Medical Economics Co. 
Montvale, NJ: Thomson Healthcare; 2003. 
64 Friedman J, Little B, Brent RL, et al. Potential human terato- 
genicity of frequently prescribed drugs. Obstet Gynecol 1990;75: 
594-599. 
6.5 Dam K, Seidler F, Slotkin T. Transcriptional biomarkers distin- 
guish between vulnerable periods for developmental neurotoxic- 
ity of chlorpyrifos: implications for toxicogenomics. Brain Res 
BUN 2003;59:261-265. 
66 Tyl R, Myers C, Thomas B, et al. Three-generation reproductive 
toxicity study of dietary bisphenol A in CD Sprague-Dawley rats. 
Toxicol Sci 2002;68:121-146. 
67 Yarnada H, Furuta I, Kato E, et al. Maternal serum and amniotic 
fluid bisphenol A concentrations in the early second trimester. 
Reprod Toxicol 2002;16:735-739. 
68 Holson J, DeSesso J, Jacobson C, Farr C. Appropriate use 
of animal models in the assessment of risk during prenatal 
development: an illustration using inorganic arsenic. Teratology 
2000;62:5 1-71. 
69 Brent RL, Jensh R, Beckman D. Medical sonography: reproduc- 
tive effects and risks. Teratology 1991;44:123-146. 
70 Wilson J, Brent RL, Jordan H. Differentiation as a determinant of 
the reaction of rat embryos to x-irradiation. Proc Soc Exp Biol 
Med 1953;82:67-70. 
71 Brent RL. Commentary on bendectin and birth defects: hopefully 
the final chapter. Birth Defects Res 2003;67:79-87. 
72 Roberts C, Lowe C. Where have all the conceptions gone? Lancet 
1975;1:498499. 
73 Brent RL. Editorial: definition of a teratogen and the relationship 
of teratogenicity to carcinogenicity. Teratology 1986;34:359-360. 
74 Brent RL. Method of evaluating alleged human teratogens. Tera- 
tology 1978;17:83. 
